Literature DB >> 25480860

Benign neuromyelitis optica is rare in Japanese patients.

Akiyuki Uzawa1, Masahiro Mori2, Mayumi Muto2, Tomohiko Uchida2, Hiroki Masuda2, Saeko Masuda2, Satoshi Kuwabara2.   

Abstract

Good-outcome neuromyelitis optica (NMO) is defined as an Expanded Disability Status Scale (EDSS) score of ≤3.0 at 10 years after onset. The clinical courses of 80 consecutive patients with NMO were analyzed to identify the frequency and features of Japanese patients with good-outcome NMO. Of the 80 patients, 37 had a disease duration of >10 years; of these, eight (21.6%) presented a good outcome. These cases presented lower EDSS scores during the early phase of disease compared with those with conventional NMO. However, half of these patients developed severe disabilities later on, indicating that truly benign NMO is rare.
© The Author(s), 2014.

Entities:  

Keywords:  Benign; Expanded Disability Status Scale; good outcome; neuromyelitis optica

Mesh:

Year:  2014        PMID: 25480860     DOI: 10.1177/1352458514560927

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

1.  AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders.

Authors:  Susanna Asseyer; Hiroki Masuda; Masahiro Mori; Judith Bellmann-Strobl; Klemens Ruprecht; Nadja Siebert; Graham Cooper; Claudia Chien; Ankelien Duchow; Jana Schließeit; Jia Liu; Kazuo Sugimoto; Akiyuki Uzawa; Ryohei Ohtani; Friedemann Paul; Alexander U Brandt; Satoshi Kuwabara; Hanna G Zimmermann
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-05-04

Review 2.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Authors:  Kazuo Fujihara; Jeffrey L Bennett; Jerome de Seze; Masayuki Haramura; Ingo Kleiter; Brian G Weinshenker; Delene Kang; Tabasum Mughal; Takashi Yamamura
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.